1573 related articles for article (PubMed ID: 30241056)
1. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
2. Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome.
Piña-Garza JE; Montouris GD; Vekeman F; Cheng WY; Tuttle E; Giguere-Duval P; Duh MS; Shen V; Saurer TB; Isojarvi J
Epilepsy Behav; 2017 Aug; 73():46-50. PubMed ID: 28609734
[TBL] [Abstract][Full Text] [Related]
3. The direct cost of seizure events in severe childhood-onset epilepsies: A retrospective claims-based analysis.
Reaven NL; Funk SE; Lyons PD; Story TJ
Epilepsy Behav; 2019 Apr; 93():65-72. PubMed ID: 30831405
[TBL] [Abstract][Full Text] [Related]
4. The burden of illness in Lennox-Gastaut syndrome: a systematic literature review.
Strzelczyk A; Zuberi SM; Striano P; Rosenow F; Schubert-Bast S
Orphanet J Rare Dis; 2023 Mar; 18(1):42. PubMed ID: 36859290
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology, healthcare resource use, and mortality in patients with probable Lennox-Gastaut syndrome: A population-based study on German health insurance data.
Strzelczyk A; Schubert-Bast S; Simon A; Wyatt G; Holland R; Rosenow F
Epilepsy Behav; 2021 Feb; 115():107647. PubMed ID: 33358132
[TBL] [Abstract][Full Text] [Related]
6. Health Care Utilization and Costs Associated with Endometriosis Among Women with Medicaid Insurance.
Soliman AM; Surrey ES; Bonafede M; Nelson JK; Vora JB; Agarwal SK
J Manag Care Spec Pharm; 2019 May; 25(5):566-572. PubMed ID: 31039061
[TBL] [Abstract][Full Text] [Related]
7. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
8. The High Direct Medical Costs of Prader-Willi Syndrome.
Shoffstall AJ; Gaebler JA; Kreher NC; Niecko T; Douglas D; Strong TV; Miller JL; Stafford DE; Butler MG
J Pediatr; 2016 Aug; 175():137-43. PubMed ID: 27283463
[TBL] [Abstract][Full Text] [Related]
9. Development of a classifier to identify patients with probable Lennox-Gastaut syndrome in health insurance claims databases via random forest methodology.
Vekeman F; Piña-Garza JE; Cheng WY; Tuttle E; Giguère-Duval P; Oganisian A; Damron J; Sheng Duh M; Shen V; Saurer TB; Montouris GD; Isojarvi J
Curr Med Res Opin; 2019 Aug; 35(8):1415-1420. PubMed ID: 30870597
[No Abstract] [Full Text] [Related]
10. Health Care Utilization and Economic Burden in Patients with Central Precocious Puberty: An Assessment of the Commercially Insured and Medicaid Populations.
Klein K; Soliman AM; Bonafede M; Nelson JK; Grubb E
J Manag Care Spec Pharm; 2019 Jul; 25(7):836-846. PubMed ID: 31232203
[TBL] [Abstract][Full Text] [Related]
11. Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study.
Chin RFM; Pickrell WO; Guelfucci F; Martin M; Holland R
Seizure; 2021 Oct; 91():159-166. PubMed ID: 34161904
[TBL] [Abstract][Full Text] [Related]
12. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
13. Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome.
François C; Stern JM; Ogbonnaya A; Lokhandwala T; Landsman-Blumberg P; Duhig A; Shen V; Tan R
J Mark Access Health Policy; 2017; 5(1):1318691. PubMed ID: 28740620
[No Abstract] [Full Text] [Related]
14. Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by medicaid or private insurance.
Ivanova JI; Birnbaum HG; Chen L; Duhig AM; Dayoub EJ; Kantor ES; Schiller MB; Phillips GA
Am J Manag Care; 2011 Aug; 17(8):e314-23. PubMed ID: 21851139
[TBL] [Abstract][Full Text] [Related]
15. Management of Lennox-Gastaut syndrome beyond childhood: A comprehensive review.
Samanta D
Epilepsy Behav; 2021 Jan; 114(Pt A):107612. PubMed ID: 33243685
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK.
Benedict A; Verdian L; Maclaine G
Pharmacoeconomics; 2010; 28(3):185-99. PubMed ID: 20151724
[TBL] [Abstract][Full Text] [Related]
17. Lennox-Gastaut syndrome: a comprehensive review.
Asadi-Pooya AA
Neurol Sci; 2018 Mar; 39(3):403-414. PubMed ID: 29124439
[TBL] [Abstract][Full Text] [Related]
18. Budget impact analysis of antiepileptic drugs for Lennox-Gastaut syndrome.
Skornicki M; Clements KM; O'Sullivan AK
J Manag Care Spec Pharm; 2014 Apr; 20(4):400-6. PubMed ID: 24684645
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
